Adlai Nortye is a global clinical-stage biopharmaceutical company based in North Brunswick, New Jersey and Hangzhou, China, dedicated to transforming deadly cancer into a chronic and eventually curable disease. Leveraging its dual R&D presence, we are pioneering innovative immuno-oncology medicines.

Our mission is to identify and develop differentiated innovative medicines that help people live better, live longer.

Adlai Nortye’s pipeline focuses on two key areas: RAS-targeting therapies, including AN9025 and AN4035, and next-generation cancer immunotherapies, such as AN8025 and AN4005, designed to activate cancer immunity in novel ways. We are committed to advancing patient care through groundbreaking research and development.

AN4035 | Adlai Nortye

Product description

Adlai Nortye 杭州, China

Price: N/A

Adlai Nortye
杭州, China